Posted by Michael Wonder on 12 Nov 2021
First in class medicine recommended for treatment of rare blood vessel inflammation
12 November 2021 - EMA has recommended granting a marketing authorisation in the European Union for Tavneos (avacopan), a first in class medicine to treat adult patients suffering from two forms of a rare multi-system autoimmune condition.
EMA’s CHMP based its recommendation for approval on data from a Phase 3 clinical trial.
